Investors are watching to see if remission will be maintained in patients with ulcerative colitis.
Shares of Abivax, a biotech company from France, showed the best performance within the European Stoxx 600 index, Bloomberg reports. The company's stock skyrocketed by more than 1300% this year, driven by positive trial results for a treatment for chronic bowel diseases. Analysts at Morgan Stanley note that the success or failure of the trials will determine whether Abivax's shares will rise even further or, conversely, plummet by more than 90%.
Shares of the French biotechnology company Abivax surged by more than 1300% in 2025, showing the best performance within the European Stoxx 600 index, Bloomberg reports, citing trading data. If at the beginning of the year Abivax's market capitalization was less than $500 million, it has now exceeded $8 billion due to the rapid rise in stock prices.
Investors are watching to see if remission will be maintained in patients with ulcerative colitis who took obefazimod, Bloomberg notes. Abivax is expected to publish the results of this study in the second quarter of 2026: if successful, it will have the opportunity to apply for drug registration with regulatory authorities. Abivax also plans to publish the results of the interim phase of the obefazimod trial for the treatment of Crohn's disease in the second half of the year.
Abivax is expected to publish the results of the late-stage trial of obefazimod in the second quarter of 2026, and if successful, will be able to apply for approval of the drug from regulatory authorities. The company will also present the results of the interim trials of the drug for the treatment of Crohn's disease in the second half of the year.
The trial results were described as "exceptional and completely unexpected," noted Van Lanschot Kempen analyst Sebastian van der Schut. According to him, they showed that the effectiveness of the Abivax tablet is among the highest of all options, including injectable drugs.
The stakes for Abivax were very high, Bloomberg notes. Initially, the company considered obefazimod as a potential drug against HIV. The success or failure of the trials of this drug for the treatment of ulcerative colitis or Crohn's disease is a key driver of stock dynamics, Morgan Stanley analysts noted. In their opinion, in a positive scenario, American depositary receipts of Abivax, which are traded on Nasdaq in the U.S., could rise another 40% from current levels. In a negative scenario, they risk collapsing by more than 90%.
